Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

Inclusion Criteria:

* Patients have provided a signed Informed Consent Form
* Age: 18-75 years old
* Histologically confirmed diagnosis of esophageal squamous cell carcinoma
* Patients have Received and progressed on 1 line of prior Fluoropyrimidine, platinum or taxane based palliative chemotherapy
* Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria
* Life expectancy ≥ 3 months
* Karnofsky score ≥70
* Patient has adequate bone marrow and organ function

  * Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L
  * Platelets ≥ 75 x 109/L
  * Hemoglobin ≥ 9.0 g/dL
* Patient has adequate liver function

  * AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis)
  * Serum bilirubin ≤ 2 x ULN
* Creatinine ≤ 1.5 times ULN
* No malabsorption or other gastrointestinal disorders affecting drug absorption.
* No serious complications such as active gastrointestinal hemorrhage, perforation, jaundice, gastrointestinal obstruction, non cancerous fever \> 38 ℃.
* Expect good compliance

Exclusion Criteria:

* Patient has received previous treatment with EGFR inhibitors
* Patient is currently receiving Phenytoin, rifampin, barbiturates, C Masi Bing
* Known severe hypersensitivity to Icotinib or any of the excipients of this product
* CNS metastases without radiotherapy and/or surgery
* Patients with treated CNS metastases may participate in this trial,except for those who must receive hormone therapy and those whose prior hormone therapy for CNS metastases is less than 4 weeks
* Evidence of clinically active Interstitial Lung Diseases
* Severe systemic disease out of control such as unstable or uncompensated respiratory,cardiac,liver,renal diseases
* Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of nonmelanoma skin cancer or cervical carcinoma in situ
* psychiatric illness that would prevent the patient from giving informed consent
* Patient is concurrently using other approved or investigational antineoplastic agent
* Pregnant or lactating women